Valuation: Roche Holding AG

Market Cap 296B 353B 318B 269B 504B 33,611B 507B 3,556B 1,389B 17,444B 1,326B 1,297B 56,105B P/E 2026 *
20x
P/E 2027 * 18.2x
Enterprise Value 307B 366B 329B 278B 523B 34,844B 526B 3,687B 1,440B 18,084B 1,375B 1,345B 58,164B EV / Sales 2026 *
4.88x
EV / Sales 2027 * 4.56x
Free-Float
88.78%
Yield 2026 *
2.7%
Yield 2027 * 2.76%

Last Transcript: Roche Holding AG

Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 345B
+3.62%+1.68%+48.80%+98.41% 1,040B
+2.13%-1.76%+33.04%+61.88% 599B
+3.32%+4.47%+23.72%+91.59% 485B
+3.80%+3.21%+73.99%+41.69% 350B
+3.09%+3.03%+29.59%+45.42% 345B
+2.82%+2.20%+17.90%+40.15% 272B
+3.40%+0.99%-3.44%+12.08% 244B
+3.21%+3.15%+45.01%+49.99% 223B
+3.80%+4.56%+29.59%+97.73% 183B
Average +2.58%+1.90%+33.13%+59.88% 415.87B
Weighted average by Cap. +2.32%+1.53%+36.79%+68.68%

Financials

2026 *2027 *
Net sales 62.93B 75B 67.43B 57.03B 107B 7,137B 108B 755B 295B 3,704B 282B 275B 11,914B 65.87B 78.51B 70.59B 59.7B 112B 7,471B 113B 791B 309B 3,878B 295B 288B 12,471B
Net income 14.63B 17.44B 15.68B 13.26B 24.9B 1,660B 25.06B 176B 68.58B 861B 65.49B 64.07B 2,771B 16.37B 19.51B 17.54B 14.84B 27.86B 1,857B 28.03B 196B 76.72B 964B 73.26B 71.67B 3,100B
Net Debt 10.88B 12.96B 11.65B 9.86B 18.51B 1,234B 18.62B 131B 50.96B 640B 48.66B 47.61B 2,059B 4.26B 5.07B 4.56B 3.86B 7.24B 483B 7.29B 51.07B 19.94B 251B 19.04B 18.63B 806B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Roche Holding AG